Clinical Efficacy and Safety of Vancomycin Continuous Infusion in Patients Treated at Home in an Outpatient Parenteral Antimicrobial Therapy Program.
OPAT at home
adverse event monitoring
continuous infusion
elastomeric pump
satisfaction survey
therapeutic drug monitoring
vancomycin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
15
04
2022
revised:
10
05
2022
accepted:
21
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
29
5
2022
Statut:
epublish
Résumé
Vancomycin is commonly used in outpatient parenteral antimicrobial therapy (OPAT) of Gram-positive infections. Therapeutic drug monitoring and adverse event monitoring pose a challenge. Outcome data of vancomycin in OPAT (vOPAT) are limited. The study aim was to report the safety and efficacy of a structured vOPAT program implemented in the University Hospitals Leuven. The program provides continuous elastomeric infusion of vancomycin at home with biweekly follow-up at the outpatient clinic. Demographics, clinical, biochemical and treatment parameters, target attainment parameters and clinical outcomes were recorded. An e-survey was conducted to assess patient satisfaction. Thirty-five vOPAT episodes in 32 patients were included. During 206 follow-up consultations, 203 plasma concentration measurements were registered with a median vancomycin plasma concentration of 22.5 mg/L (range 6.6-32.0). The majority of concentrations (68.5%) were within the therapeutic range (20.0-25.0 mg/L). Adverse event rates, including drug- (5.7%) and catheter-related (5.7%) events, were low. For 32 vOPAT episodes, a clinical cure rate of 100% was observed. All patients who completed the e-survey were satisfied with their vOPAT course. These findings show that a structured vOPAT program with rigorous follow-up provides safe and effective ambulatory treatment of patients with vancomycin in continuous infusion.
Identifiants
pubmed: 35625346
pii: antibiotics11050702
doi: 10.3390/antibiotics11050702
pmc: PMC9137986
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pharmacotherapy. 2020 Apr;40(4):357-362
pubmed: 32090347
JAC Antimicrob Resist. 2021 Jan 18;3(1):dlaa113
pubmed: 34223065
Int J Antimicrob Agents. 2022 May;59(5):106579
pubmed: 35341931
BMC Pharmacol Toxicol. 2018 Aug 6;19(1):50
pubmed: 30081959
Antibiotics (Basel). 2022 Apr 05;11(4):
pubmed: 35453237
Clin Infect Dis. 2013 Aug;57(3):419-24
pubmed: 23572486
Clin Microbiol Infect. 2020 May;26(5):572-578
pubmed: 31446152
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9
pubmed: 26856841
J Clin Pharm Ther. 2001 Dec;26(6):445-51
pubmed: 11722682
BMC Anesthesiol. 2015 Jun 27;15:95
pubmed: 26116239
J Antimicrob Chemother. 2012 Dec;67(12):2970-3
pubmed: 22915464
Clin Orthop Relat Res. 2022 Jan 1;480(1):139-146
pubmed: 34351311
Clin Infect Dis. 2019 Jan 1;68(1):e1-e35
pubmed: 30423035
Infect Dis Now. 2020 Oct 22;51(1):39-49
pubmed: 33576336
J Antimicrob Chemother. 2018 Sep 1;73(9):2540-2545
pubmed: 29982449
J Antimicrob Chemother. 2008 Jul;62(1):168-71
pubmed: 18334494
Infect Control Hosp Epidemiol. 2018 Aug;39(8):947-954
pubmed: 29893658
Int J Clin Pharm. 2022 Apr;44(2):557-563
pubmed: 35157228
Ann Pharmacother. 2011 Nov;45(11):1329-37
pubmed: 21990938
J Arthroplasty. 2019 Feb;34(2S):S463-S475
pubmed: 30348582
Crit Care. 2020 Jun 18;24(1):359
pubmed: 32552817
Infection. 2020 Jun;48(3):357-366
pubmed: 32060859
J Pharm Pract. 2015 Oct;28(5):462-8
pubmed: 25107418
J Clin Pharmacol. 2020 Mar;60(3):384-390
pubmed: 31630403
J Arthroplasty. 2022 Feb;37(2):373-378
pubmed: 34740790
J Pharm Technol. 2022 Feb;38(1):10-17
pubmed: 35141722
J Orthop Trauma. 2020 Jan;34(1):30-41
pubmed: 31567902
Rev Esp Quimioter. 2021 Jun;34(3):200-206
pubmed: 33724755
J Pediatric Infect Dis Soc. 2020 Jul 13;9(3):281-284
pubmed: 32659787
Int J Antimicrob Agents. 2009 Dec;34(6):570-4
pubmed: 19744837
J Antimicrob Chemother. 2011 Feb;66(2):408-15
pubmed: 21118914
J Antimicrob Chemother. 2014 Mar;69(3):805-8
pubmed: 24107387
Emerg Infect Dis. 2005 Oct;11(10):1558-64
pubmed: 16318696
Clin Infect Dis. 2018 Jan 6;66(1):11-19
pubmed: 29020202
Braz J Infect Dis. 2021 Mar-Apr;25(2):101560
pubmed: 33716018
Drugs. 2000;59 Suppl 3:1-8; discussion 47-9
pubmed: 10845408
J Antimicrob Chemother. 2016 Dec;71(12):3568-3574
pubmed: 27530754